Inflammatix Announces Three Landmark Publications in Nature Medicine that Redefine Acute Infection and Sepsis Diagnosis and Treatment
Inflammatix cracks the code of sepsis with an AI-powered test that outperforms the standard of care
SEPSIS-SHIELD study validates TriVerity™ as a breakthrough test that can transform hospital triage by providing early clarity on both infection type and illness severity
SUNNYVALE, Calif., Sept. 30, 2025 /PRNewswire/ — Inflammatix, a pioneer in host-response diagnostics, today announced the publication of three manuscripts in Nature Medicine that will redefine how patients with suspected sepsis are diagnosed and treated, potentially offering faster answers for physicians, better outcomes for patients, and measurable cost savings for hospitals.
